R-107 / Claritas Pharma - LARVOL DELTA

Claritas Announces Completion of IND-Enabling In Vitro Genotoxicity Studies with R-107 (GlobeNewswire) - "Claritas Pharmaceuticals, Inc....announced that it has completed GLP genotoxicity studies of R-107....'We plan to use these important data to gain FDA approval for our planned Phase 1 clinical trial in human subjects that will be initiated this year at CMAX in Adelaide, Australia'....The data in both the Ames Assay and the in vitro micronucleus test confirm that R-107 does not have any carcinogenic ability, which positively contributes to its safety profile and moves the drug closer to initiation of human clinical testing in a Phase I study."

New P1 trial • Preclinical • Infectious Disease • Novel Coronavirus Disease